At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 66 enrolled
Drug / intervention
Solriamfetol 75 MG +2 moredrug
Likely dose
Solriamfetol 75 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Solriamfetol for ADHD in Adults: A Double-Blind Placebo Controlled Pilot Study
In Brief
A Phase 3 clinical trial evaluating Solriamfetol 75 MG, Solriamfetol 150 MG, and 1 other intervention for Attention Deficit Hyperactivity Disorder. Completed, enrolled 66 participants across 1 site.
Detailed Summary
A double-blind, placebo controlled study of solriamfetol for adults age 18 to 65 with diagnosis of Attention Deficit Hyperactivity Disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartAug 2021
Primary CompletionJan 2023
TodayJul 2026
First PostedApr 9, 2021
Enrollment StartAug 6, 2021
Primary CompletionJan 27, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.2 years ago
Interventions
Solriamfetol 75 MGdrug
Daily oral consumption
Solriamfetol 150 MGdrug
Daily oral consumption
Placeboother
Placebo